CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Buy" by Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have received an average recommendation of "Buy" from the ten research firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $63.88.

Several research analysts have commented on CGON shares. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Monday, March 31st. TD Cowen initiated coverage on CG Oncology in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $55.00 price target on shares of CG Oncology in a report on Friday, March 7th.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

Institutional Trading of CG Oncology

A number of institutional investors have recently made changes to their positions in the company. State Street Corp lifted its stake in CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after purchasing an additional 717,722 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in CG Oncology by 876.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company's stock valued at $1,006,000 after acquiring an additional 23,931 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of CG Oncology by 59.1% in the third quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company's stock valued at $1,172,000 after purchasing an additional 11,542 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of CG Oncology in the fourth quarter worth $411,000. Finally, Neo Ivy Capital Management acquired a new position in CG Oncology during the 3rd quarter worth $1,120,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Remove Ads

CG Oncology Price Performance

Shares of NASDAQ:CGON traded up $1.65 during trading on Wednesday, hitting $19.28. The company had a trading volume of 1,714,584 shares, compared to its average volume of 706,904. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -13.58 and a beta of 1.24. The company has a fifty day simple moving average of $25.19 and a two-hundred day simple moving average of $30.30. CG Oncology has a one year low of $14.80 and a one year high of $46.99.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The business had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.11 million. On average, equities research analysts anticipate that CG Oncology will post -1.31 earnings per share for the current year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.